Gene, Gene Expression and In-Vitro - Clinical Research Informer

Start-up to study peptides that modulate gene expression

Drug Discovery World

AUGUST 31, 2023

Other potential cancer indications with ongoing in vitro work include breast and ovarian cancer. HBCI’s CEO, Dr Bomi Framroze said: “HBCI is at the forefront of research in using peptides to modulate gene expression. Our first therapeutic target is resistant castration-resistant prostate cancer (CRPC).

Gene Expression

Gene Expression Gene In-Vitro Research

Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk

Pharmaceutical Technology

AUGUST 11, 2022

Alnylam Pharmaceuticals and collaborators have identified rare mutations in the INHBE gene that is expressed in the liver, related to a lower waist-to-hip ratio for body mass index (BMI), which is often used as an indicator of abdominal fat and is correlated with the risk of type 2 diabetes (T2D) and coronary heart disease.

Gene

Gene Biobanking Gene Expression In-Vitro

Quantitative approach on understanding how epigenetic switches control gene expression

Scienmag

DECEMBER 10, 2020

For this, they successfully generated reconstituted chromatin bearing histone modifications in vitro. Credit: Nucleic Acids Research Scientists at Tokyo Institute of Technology decipher how to quantitatively assess the effects of specific epigenetic changes on the rate of transcription by developing a mathematical model.

Gene Expression

Gene Expression In-Vitro Gene Scientist

Phase Ib study proves efficacy of SFX-01 coated tablet formation

Drug Discovery World

AUGUST 22, 2023

In addition, total blood levels of sulforaphane (SFN) and SFN-metabolites were confirmed in the micromolar range, where efficacy is seen in vitro. Evgen Pharma has revealed the final data from its Phase Ib healthy volunteer study using the company’s new enteric coated tablet formation of its lead asset SFX-01.

Gene Expression

Gene Expression In-Vitro Gene Trials

Biologics – The Next Step in Revolutionary Medication

Roots Analysis

JANUARY 14, 2024

Expression Systems for Biologics The processes associated with the manufacturing of biopharmaceuticals are complex and require highly sterile and aseptic conditions. This can be attributed to the fact that the production of biopharmaceuticals requires living expression systems.

Contract Manufacturing

Contract Manufacturing Manufacturing Protein Bacteria

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Delveinsight

JANUARY 18, 2021

Angelman syndrome is a result of the missing or dysfunctional gene known as UBE3A. The gene is responsible for the normal and healthy development of an individual physically as well intellectually. Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system.

Marketing

Marketing Gene Drugs Protein

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

AUGUST 3, 2022

Plus, in numerous in vitro experiments, the conjugate has been able to specifically enter ? 3 positive human cells and silence the targeted genes. Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Nanoparticles 6.

Bioavailability

Bioavailability In-Vivo RNA In-Vitro

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA

RNA Protein DNA In-Vivo

Fibrosis research: Advances and challenges

Drug Discovery World

JANUARY 24, 2024

Fibrocor is on track to complete all IND-enabling work to support IND filing and initiation of clinical trials in 2024. Phase I of the clinical program will dose healthy volunteers with single ascending doses of FIB992 before proceeding to a multiple ascending dose study where the drug is administered for a two-week period.

Research

Research Gene Expression Drugs Development

The use of base editing in stem-cell based therapies

Drug Discovery World

JANUARY 23, 2023

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. Adult fibroblasts were cultured in a cocktail of transcription factors to reactivate embryonic gene expression patterns 2.

Gene Editing

Gene Editing Gene Engineer DNA

RNA Therapeutics: A Novel Approach to Treating Diseases

Roots Analysis

OCTOBER 22, 2023

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.

RNA

RNA Protein Genetics Gene Expression

FAIR Game: making data work harder in the race to market

Drug Discovery World

OCTOBER 17, 2022

For pharma and biotech companies – whether working on small or large molecule drugs, or cell and gene therapies – this means empowering scientists with better and faster data management approaches, best practices, and leading technologies so they can pinpoint new molecules and formulations and modify existing ones more easily and quickly.

Marketing

Marketing Scientist Gene Expression Drugs

What to expect from SLAS Europe 2023

Drug Discovery World

APRIL 21, 2023

The 2022 podium winner was Viktoria Zieger, Imtek – University of Freiburg, who presented: Selective High- Throughput Deposition of Microtumors for in vitro Studies on 3D Tumor Models. SLAS Europe 2023 will take place 22-26 May in Brussels, Belgium, where attendees will embrace the theme Science Set in Motion.

Doctors

Doctors Doctor Genetics In-Vitro

Bristol Myers Squibb Statement on Istodax® (romidepsin) Relapsed/Refractory Peripheral T-cell Lymphoma U.S. Indication

The Pharma Data

AUGUST 3, 2021

In 2011, Celgene Corporation, now a wholly owned subsidiary of Bristol Myers Squibb, received accelerated approval by the U.S. Based on this outcome, Bristol Myers Squibb made the decision to withdraw the PTCL indication from the U.S. senior vice president, Hematology Development, Bristol Myers Squibb.

Nurses

Nurses In-Vitro Gene Expression Medicine

Clinical Research Informer

Start-up to study peptides that modulate gene expression

Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk

Trending Sources

Quantitative approach on understanding how epigenetic switches control gene expression

Phase Ib study proves efficacy of SFX-01 coated tablet formation

Biologics – The Next Step in Revolutionary Medication

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Cell-penetrating peptides as a delivery system for oligonucleotides

What the Glycome Can Tell Us About Persistent HIV Infection

Fibrosis research: Advances and challenges

The use of base editing in stem-cell based therapies

RNA Therapeutics: A Novel Approach to Treating Diseases

FAIR Game: making data work harder in the race to market

What to expect from SLAS Europe 2023

Bristol Myers Squibb Statement on Istodax® (romidepsin) Relapsed/Refractory Peripheral T-cell Lymphoma U.S. Indication

Stay Connected